Research study Program year 2022 Source: CMS Open Payments

Nn9924-4309

Research payments

$25,425

80 payments

Through program year 2022, $25,425 in research payments was reported against Nn9924-4309, across 80 payments, paid by Novo Nordisk AS.

Paid by: Novo Nordisk AS
ClinicalTrials.gov: No trial number was reported for this study

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$750	1
2021	Research	$18,850	57
2020	Research	$5,825	22

Breakdown

Who paid Research payments · program years 2020–2022

Novo Nordisk AS $25,425 80 payments

Who received the money Research payments · program years 2020–2022

Mark Schroeder Medical Oncology · Saint Louis, MO $3,025 8 payments
Michael Morse Hematology & Oncology · Durham, NC $2,900 10 payments
Benglow Consulting Organisation paid for research $2,875 3 payments
Eliahu Feen Neurocritical Care · Marietta, GA $2,350 11 payments
Jamie Dwyer Nephrology · Nashville, TN $2,275 9 payments
Richard Bach Interventional Cardiology · Saint Louis, MO $2,225 7 payments
Kevin Martin Nephrology · St Louis, MO $1,775 7 payments
Fatima Rodriguez Cardiovascular Disease · Stanford, CA $1,725 4 payments
David Bushinsky Nephrology · Rochester, NY $1,400 6 payments
Gustavo Rodriguez Neurological Surgery · El Paso, TX $1,175 5 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

1 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

Bernard Chaitman Saint Louis, MO Named on 3 payments

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.